Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

X
Trial Profile

Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 11 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lasmiditan (Primary)
  • Indications Migraine
  • Focus Registrational; Therapeutic Use
  • Acronyms CENTURION
  • Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
  • Most Recent Events

    • 24 Mar 2023 Results from the open-label extension of the CENTURION randomized trial published in the Cephalalgia
    • 10 Dec 2022 Results from the open label extension evaluating dose optimization, patterns of use, migraine-related disability, and quality of life during lasmiditan treatment, presented at the 16th European headache federation COngress
    • 17 Sep 2022 Results (n=208) of post hoc analysis of randomized controlled phase 3 CENTURION Trial assessing the safety profile of lasmiditan in the Chinese population published in the Advances in Therapy

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top